【摘要】 目的评价乌司他丁治疗急性呼吸窘迫综合征（ARDS）的效果。方法利用计算机检索已公开发表的有关乌司他丁治疗ARDS患者疗效的文献。按照纳入标准、排除标准纳入合格文献并进行质量评价。采用Rev Man 5.3统计软件进行Meta分析。结果共纳入17项随机对照研究,共1 101例患者,其中试验组561例,对照组540例。荟萃分析研究结果显示:ARDS患者给予乌司他丁治疗与对照组相比PaO₂、PaO₂/FiO₂、APACHE评分、血管外肺水指数（EVLWI）、住ICU时间、住院时间及病死率有统计学意义（P<0.05）,合并均数差（MD）或相对危险度（RR）及95%置信区间（CI）依次为10.78（5.92,15.65）,57.71（43.98,71.43）,-4.15（-5.01,-3.29）,-2.37（-3.07,-1.68）,-3.51（-5.63,-1.40）,-9.27（-11.81,-6.74）,0.45（0.35,0.58）。两组治疗后PaCO₂差异无统计学意义（P>0.05）。结论 ARDS患者给予乌司他丁能提高患者Pa O₂、氧合指数,改善APACHE评分、EVLWI,缩短住ICU时间、住院时间,降低病死率。更多还原

【Abstract】 Objective To study the effect of ulinastatin in the patients with acute respiratory distress syndrome（ARDS）. Methods Literatures about the patients with ARDS treated with ulinastatin were electrically searched. Meta-analysis was performed by Rev Man 5.3 software after the data of qualified studies were included in consistence with the criteria of inclusion and exclusion. Results 17 studies were including 1 101 cases（experimental group 561, control group 540） met the inclusion criteria. Results of Meta-analysis showed that there were significant difference（P<0.5） between the experimental group and control group in PaO₂, PaO₂/FiO₂, APACHE scores, EVLWI, the ICU days, the hospital days and the motality. The relative risks（RR）/mean difference（MD） and 95% confidence intervals（CI） were 10.78（5.92, 15.65）, 57.71（43.98, 71.43）,-4.15（-5.01,-3.29）,-2.37（-3.07,-1.68）,-3.51（-5.63,-1.40）,-9.27（-11.81,-6.74）, 0.45（0.35, 0.58） respectively. However, there were no significant difference in the level of Pa CO₂ between the two groups（P>0.05）. Conclusion Patients with ARDS treated with ulinastatin had better Pa O₂, Pa O₂/Fi O₂, APACHE scores and EVLWI, shorter ICU days and hospital days, lower motality than control group.更多还原